Evaxion establishes new AI-derived precision cancer vaccine concept
12. Dezember 2024 08:00 ET
|
Evaxion Biotech
Evaxion’s AI-Immunology™ platform allows for the design of precision cancer vaccines targeting non-conventional ERV tumor antigens shared across patientsNovel preclinical data confirms the...
Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress
02. Dezember 2024 08:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, December 2, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present...
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
09. September 2024 07:00 ET
|
Evaxion Biotech
New pre-clinical data demonstrates that the novel EVX-B2 mRNA vaccine candidate triggers a targeted immune response The specific immune response leads to the elimination of the gonorrhea bacteriaThe...
Siyata Mobile Inc. to Showcase Portfolio at IWCE 2024
11. März 2024 11:43 ET
|
Siyata Mobile Inc.
Siyata Mobile (NASDAQ:SYTA) will host an exhibitor's booth at the International Wireless Communications Expo ("IWCE") 2024 in partnership with Verizon
Siyata Receives First Order for SD7 Handsets in Higher Education
20. Dezember 2023 08:59 ET
|
Siyata Mobile Inc.
VANCOUVER, British Columbia, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a global developer and vendor of Push-to-Talk over Cellular (PoC)...
A Year End Message from Marc Seelenfreund, Siyata Mobile’s CEO
12. Dezember 2023 08:05 ET
|
Siyata Mobile Inc.
VANCOUVER, British Columbia, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a global vendor of Push-to-Talk over Cellular (PoC) devices and...
Siyata Mobile Announces $900,000 Follow-On Orders
07. Dezember 2023 10:48 ET
|
Siyata Mobile Inc.
Siyata Mobile Inc. (Nasdaq: SYTA) received a $900,000 order for existing international Defense and EMS customers for the Company’s UV350 and PTT devices
Global In-Vitro Diagnostics Market Size is Projected to Reach USD 116.32 Billion by 2030, with a CAGR of 5.2%: Straits Research
31. Oktober 2023 14:50 ET
|
Straits Research
New York, United States, Oct. 31, 2023 (GLOBE NEWSWIRE) -- In-vitro diagnostics, or IVD, are medical devices and reagents used to examine body fluids and tissues to diagnose diseases, conditions,...
Point of Care Diagnostics Market to Hit 12.7% CAGR with Glucose Monitoring Products Driving Growth During 2021–2028 | The Insight Partners
26. Oktober 2023 07:55 ET
|
The Insight Partners
Pune, India, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Point-of-care testing (POCT) is essential for the rapid detection of analytes near to the patient, which facilitates in disease diagnosis, monitoring,...
Albumin & Creatinine Tests Market revenue to hit USD 19 Billion by 2035, says Research Nester
22. August 2023 07:30 ET
|
Research Nester
New York, Aug. 22, 2023 (GLOBE NEWSWIRE) -- The global Albumin & Creatinine Tests market size is slated to expand at ~19% CAGR between 2023 and 2035. The market is poised to garner a revenue of...